{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:38:46Z","timestamp":1790019526392,"version":"4.0.1"},"reference-count":69,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms associated with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic correlates of disease progression in MDS by profiling active genomic regulatory regions and their transcriptional impact using H3K27ac chromatin immunoprecipitation\u2013sequencing and RNA-sequencing analysis on CD34+ bone marrow progenitors cells isolated from a prospective cohort of 86 and 357 patients, respectively. Our analysis revealed distinct patterns of genomic region activation and transcriptional regulation across different disease stages such as low-risk MDS, high-risk MDS, and sAML. Unexpectedly, unsupervised clustering revealed a subset of patients with low-risk MDS displaying regulatory and transcriptional profiles similar to those of high-risk MDS and sAML, highlighting early molecular events that may predispose patients to disease progression. This subset is characterized by PU.1 genomic occupancy in regions linked to immune and inflammatory responses, increased T-cell and natural killer cell activation, and a higher frequency of SRSF2 mutations. Clinically, patients in this group exhibit greater susceptibility to infections and cardiovascular events, along with an elevated risk of disease progression, resulting in significantly reduced overall survival. Functional studies demonstrated that PU.1 inhibition suppresses MDS cell proliferation and clonogenicity, as impaired PU.1 binding inhibits the activation of key transcriptional programs involved in disease advancement. Collectively, these findings identify epigenetic factors that predispose patients with low-risk MDS to progression to high-risk MDS and, ultimately, sAML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030760","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:27:57Z","timestamp":1768505277000},"page":"2358-2374","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2285-2711","authenticated-orcid":false,"given":"Veronica","family":"Vallelonga","sequence":"first","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-0258","authenticated-orcid":false,"given":"Francesco","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-1142","authenticated-orcid":false,"given":"Matteo","family":"Zampini","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-3889","authenticated-orcid":false,"given":"Elena","family":"Riva","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-4854","authenticated-orcid":false,"given":"Giulia","family":"Maggioni","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0928-5155","authenticated-orcid":false,"given":"Denise","family":"Ventura","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"3Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Saba","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Termanini","sequence":"additional","affiliation":[{"name":"4Human Technopole, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-0502","authenticated-orcid":false,"given":"Sara","family":"Polletti","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-9087","authenticated-orcid":false,"given":"Elena","family":"Prosperini","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-5652","authenticated-orcid":false,"given":"Laura","family":"Crisafulli","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"5Institute for Genetic and Biomedical Research, Milan Unit, Consiglio Nazionale delle Ricerche, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-759X","authenticated-orcid":false,"given":"Alessia","family":"Campagna","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Ferrari","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0867-0291","authenticated-orcid":false,"given":"Nicole","family":"Pinocchio","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"3Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Todisco","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"3Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-6321","authenticated-orcid":false,"given":"Silvia","family":"Pedretti","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"6Rodolfo Paoletti Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-5703","authenticated-orcid":false,"given":"Michela","family":"Calvi","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"7Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-1710","authenticated-orcid":false,"given":"Clara","family":"Di Vito","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"7Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-0952","authenticated-orcid":false,"given":"Domenico","family":"Mavilio","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"7Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-3619","authenticated-orcid":false,"given":"Nico","family":"Mitro","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"6Rodolfo Paoletti Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-1189","authenticated-orcid":false,"given":"Francesca","family":"Ficara","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"5Institute for Genetic and Biomedical Research, Milan Unit, Consiglio Nazionale delle Ricerche, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-5970","authenticated-orcid":false,"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[{"name":"2Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"3Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-5553","authenticated-orcid":false,"given":"Serena","family":"Ghisletti","sequence":"additional","affiliation":[{"name":"1Department of Experimental Oncology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"},{"name":"6Rodolfo Paoletti Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2026051411215825700_bib1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"2026051411215825700_bib2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026051411215825700_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026051411215825700_bib4","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"11","key":"2026051411215825700_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026051411215825700_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"key":"2026051411215825700_bib7","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes","volume":"6","author":"Gerstung","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"2026051411215825700_bib8","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"2026051411215825700_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41375-019-0623-5","article-title":"Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes","volume":"34","author":"Montalban-Bravo","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2026051411215825700_bib10","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/s41467-024-46424-3","article-title":"Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes","volume":"15","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"2026051411215825700_bib11","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026051411215825700_bib12","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/s41375-023-01949-2","article-title":"Activation of distinct inflammatory pathways in subgroups of LR-MDS","volume":"37","author":"Schneider","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"2026051411215825700_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051411215825700_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-019-0173-8","article-title":"Determinants of enhancer and promoter activities of regulatory elements","volume":"21","author":"Andersson","year":"2020","journal-title":"Nat Rev Genet"},{"key":"2026051411215825700_bib15","doi-asserted-by":"crossref","first-page":"102065","DOI":"10.1016\/j.ceb.2022.01.010","article-title":"Regulating specificity in enhancer-promoter communication","volume":"75","author":"Galouzis","year":"2022","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"2026051411215825700_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrm3949","article-title":"The selection and function of cell type-specific enhancers","volume":"16","author":"Heinz","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"2026051411215825700_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41580-024-00710-6","article-title":"Enhancer selectivity in space and time: from enhancer-promoter interactions to promoter activation","volume":"25","author":"Yang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"2026051411215825700_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.tig.2016.10.003","article-title":"Regulatory enhancer-core-promoter communication via transcription factors and cofactors","volume":"32","author":"Zabidi","year":"2016","journal-title":"Trends Genet"},{"issue":"1","key":"2026051411215825700_bib19","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1002\/hem3.70073","article-title":"Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes","volume":"9","author":"Rombaut","year":"2025","journal-title":"Hemasphere"},{"issue":"12","key":"2026051411215825700_bib20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2026051411215825700_bib21","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026051411215825700_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"issue":"12","key":"2026051411215825700_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026051411215825700_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.leu.2401149","article-title":"Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia","volume":"12","author":"Span","year":"1998","journal-title":"Leukemia"},{"issue":"11","key":"2026051411215825700_bib25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026051411215825700_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandran","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"25","key":"2026051411215825700_bib27","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2026051411215825700_bib28","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2026051411215825700_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.seminhematol.2024.09.005","article-title":"Inflammation in myelodysplastic syndrome pathogenesis","volume":"61","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Semin Hematol"},{"issue":"10","key":"2026051411215825700_bib30","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/biomedicines11102613","article-title":"Emerging insights into molecular mechanisms of inflammation in myelodysplastic syndromes","volume":"11","author":"Vallelonga","year":"2023","journal-title":"Biomedicines"},{"issue":"7","key":"2026051411215825700_bib31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2026051411215825700_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"2026051411215825700_bib33","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2026051411215825700_bib34","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1093\/nar\/gkad841","article-title":"Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities","volume":"51","author":"Muller-Dott","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2026051411215825700_bib35","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1101\/gr.133744.111","article-title":"Detecting differential usage of exons from RNA-seq data","volume":"22","author":"Anders","year":"2012","journal-title":"Genome Res"},{"issue":"23","key":"2026051411215825700_bib36","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2017010165","article-title":"Risk and timing of cardiovascular death among patients with myelodysplastic syndromes","volume":"1","author":"Brunner","year":"2017","journal-title":"Blood Adv"},{"issue":"6327","key":"2026051411215825700_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"17","key":"2026051411215825700_bib38","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026051411215825700_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2026051411215825700_bib40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2005-03-0860","article-title":"Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation","volume":"106","author":"Iwasaki","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2026051411215825700_bib41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.molcel.2014.04.006","article-title":"Coregulation of transcription factor binding and nucleosome occupancy through DNA features of mammalian enhancers","volume":"54","author":"Barozzi","year":"2014","journal-title":"Mol Cell"},{"issue":"1","key":"2026051411215825700_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41594-022-00886-5","article-title":"A pioneer factor locally opens compacted chromatin to enable targeted ATP-dependent nucleosome remodeling","volume":"30","author":"Frederick","year":"2023","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"2026051411215825700_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.immuni.2010.02.008","article-title":"Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages","volume":"32","author":"Ghisletti","year":"2010","journal-title":"Immunity"},{"issue":"1","key":"2026051411215825700_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41467-019-13960-2","article-title":"Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1","volume":"11","author":"Minderjahn","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"2026051411215825700_bib45","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1101\/gr.231423.117","article-title":"Pioneering, chromatin remodeling, and epigenetic constraint in early T-cell gene regulation by SPI1 (PU.1)","volume":"28","author":"Ungerback","year":"2018","journal-title":"Genome Res"},{"issue":"12","key":"2026051411215825700_bib46","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1172\/JCI92504","article-title":"Pharmacological inhibition of the transcription factor PU.1 in leukemia","volume":"127","author":"Antony-Debre","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"2026051411215825700_bib47","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/nar\/gkt955","article-title":"Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines","volume":"42","author":"Munde","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2026051411215825700_bib48","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/s41588-024-01911-7","article-title":"Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity","volume":"56","author":"Taylor","year":"2024","journal-title":"Nat Genet"},{"issue":"10","key":"2026051411215825700_bib49","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2003-11-4089","article-title":"PU.1 determines the self-renewal capacity of erythroid progenitor cells","volume":"103","author":"Back","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2026051411215825700_bib50","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1101\/gad.13.11.1398","article-title":"Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells","volume":"13","author":"Rekhtman","year":"1999","journal-title":"Genes Dev"},{"issue":"6","key":"2026051411215825700_bib51","doi-asserted-by":"crossref","first-page":"e1001392","DOI":"10.1371\/journal.pgen.1001392","article-title":"A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1","volume":"7","author":"Wontakal","year":"2011","journal-title":"PLoS Genet"},{"issue":"15","key":"2026051411215825700_bib52","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026051411215825700_bib53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.it.2020.05.007","article-title":"Where there's smoke, there's fire: inflammation drives MDS","volume":"41","author":"Datar","year":"2020","journal-title":"Trends Immunol"},{"issue":"10","key":"2026051411215825700_bib54","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026051411215825700_bib55","doi-asserted-by":"crossref","first-page":"e20201544","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"2026051411215825700_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2012.064048","article-title":"Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia","volume":"98","author":"Kar","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2026051411215825700_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2023.11.003","article-title":"SRSF2 plays an unexpected role as reader of m(5)C on mRNA, linking epitranscriptomics to cancer","volume":"83","author":"Ma","year":"2023","journal-title":"Mol Cell"},{"issue":"15","key":"2026051411215825700_bib58","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2026051411215825700_bib59","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026051411215825700_bib60","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood-2018-04-845602","article-title":"Srsf2P95H initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from hemopoietic stem cells","volume":"132","author":"Smeets","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2026051411215825700_bib61","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2026051411215825700_bib62","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","article-title":"The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"issue":"7367","key":"2026051411215825700_bib63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"34","key":"2026051411215825700_bib64","doi-asserted-by":"crossref","first-page":"E4726","DOI":"10.1073\/pnas.1514105112","article-title":"Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"2026051411215825700_bib65","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1182\/bloodadvances.2022007804","article-title":"RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS","volume":"6","author":"Huang","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026051411215825700_bib66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/ng1361","article-title":"Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1","volume":"36","author":"Rosenbauer","year":"2004","journal-title":"Nat Genet"},{"issue":"5178","key":"2026051411215825700_bib67","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.8079170","article-title":"Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages","volume":"265","author":"Scott","year":"1994","journal-title":"Science"},{"issue":"9","key":"2026051411215825700_bib68","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1172\/JCI30525","article-title":"A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia","volume":"117","author":"Steidl","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"2026051411215825700_bib69","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nm.3936","article-title":"Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia","volume":"21","author":"Will","year":"2015","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/20\/2358\/2519506\/blood_bld-2025-030760-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/20\/2358\/2519506\/blood_bld-2025-030760-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:22:12Z","timestamp":1778772132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/20\/2358\/566023\/PU-1-activated-genomic-regions-define-low-risk-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":69,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030760","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,14]]},"published":{"date-parts":[[2026,5,14]]}}}